What the efficacy is of each of the COVID-19 vaccines that are in use in Scotland, broken down by (a) first and (b) second dose. 

Due to the presence of new and emerging COVID-19 variants of concern, vaccine efficacy is continuously monitored and assessed. Public Health England (PHE) monitors the efficacy of COVID 19 vaccinations currently approved for use in the UK.
On 14 June PHE published its most recent analysis on the effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant, first identified in India. The analysis suggests the Pfizer-BioNTech vaccine is 96% effective against hospitalisation after 2 doses and the Oxford-AstraZeneca vaccine is 92% effective against hospitalisation after 2 doses. ? Note: These data remain subject to peer review.
Table 1: Estimated vaccine effectiveness against hospitalisation
Alpha
Delta
Vaccination status
OR vs symptomatic disease
HR vs hospitalisation
VE vs hospitalisation
OR vs symptomatic disease
HR vs hospitalisation
VE vs hospitalisation
Any vaccine
Dose 1
0.51 (0.48-0.55)
0.44 (0.28-0.70)
78% (65-86)
0.69 (0.64-0.75)
0.37 (0.22-0.63)
75% (57-85)
Dose 2
0.13 (0.1-0.15)
0.64 (0.24-1.72)
92% (78-97)
0.20 (0.18-0.23)
0.29 (0.11-0.72)
94% (85-98)
Pfizer
Dose 1
0.53 (0.47-0.58)
0.32 (0.14-0.73)
83% (62-93)
0.64 (0.54-0.77)
0.10 (0.01-0.76)
94% (46-99)
Dose 2
0.06 (0.05-0.08)
0.88 (0.21-3.77)
95% (78-99)
0.12 (0.1-0.15)
0.34 (0.10-1.18)
96% (86-99)
Astrazenica
Dose 1
0.51 (0.48-0.55)
0.48 (0.30-0.77)
76% (61-85)
0.70 (0.65-0.76)
0.41 (0.24-0.70)
71% (51-83)
Dose 2
0.26 (0.21-0.32)
0.53 (0.15-1.80)
86% (53-96)
0.33 (0.28-0.39)
0.25 (0.08-0.78)
92% (75-97)
OR =odds ratio. HR = hazards ratio. VE = vaccine effectiveness. OR vs symptomatic disease. HR and VE vs hospitalisation adjusted for age, clinically extremely vulnerable groups, ethnicity and test week

These findings indicate very high levels of protection against hospitalisation with the Delta (B.1.617.2) variant with 1 or 2 doses of either vaccine.

PHE has previously published analysis showing that one dose is 17% less effective at preventing symptomatic illness from the Delta variant, compared to the Alpha (B.1.1.7) variant, first identified in the UK. However, there is only a small difference after 2 doses.

For further information and data on this analysis please see:Vaccines highly effective against hospitalisation from Delta variant
- GOV.UK (www.gov.uk) COVID-19 vaccine effectiveness
- Public library
- PHE national
- Knowledge Hub (khub.net)
Individuals who received the Moderna vaccine were not included in this efficacy analysis on the Delta (B.1.617.2) variant, as this was a very small number.
In clinical trials with a Phase 3 placebo controlled testing in over 30,000 volunteers, the Moderna mRNA-1273 vaccine showed a vaccine efficacy of 94.1% (95% CI: 89.3-96.8%). Efficacy was similar in those over 65 years. Vaccine efficacy against severe COVID-19 was 100% (95% CI: 87.0-100%). Note: Trial data do not reflect efficacy against variants as Table 1. For further information on trial-based efficacy for other vaccines currently available in Scotland please refer to COVID-19: the green book, chapter 14a
- GOV.UK (www.gov.uk)